MCMedicalCodingSoftware
J7517

J7517: Mycophenolate mofetil, oral, 250 mg

HCPCSTerminatedBETOS O1E

J7517 is a HCPCS Level II code for mycophenolate mofetil, oral, 250 mg. It belongs to the Drugs Administered Other Than Oral Method section. It was terminated on September 30, 2026 and is not valid on new claims.

This code has been terminated

CMS terminated J7517 on September 30, 2026. It stays in the file as history: a claim you are auditing from before that date may legitimately carry it, but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.

Medicare coverage: Carrier judgment

Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.

From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q4-Oct. This states Medicare’s position on the code, not on your particular claim.

Physician fee schedule statusE

Excluded from the physician fee schedule by regulation. Payment, where it exists, comes from another fee schedule (drugs via ASP, supplies via DMEPOS, and so on).

Global period: XXX

Want the dollar amount for your locality? The fee calculator applies your GPCI and the current conversion factor.

Medically Unlikely Edits: units per day

The most units of J7517 Medicare will pay on one date of service. Bill more on a single line and it is denied. The limit is not the same in every setting, so the row that matters is the one matching the claim you are building.

practitioner
0, never payable
MAI 3: Date of Service Edit: Clinical · Oral Medication; Not Payable
outpatient
16 units
MAI 3: Date of Service Edit: Clinical · Clinical: Data
DME supplier
1440 units
MAI 3: Date of Service Edit: Clinical · Prescribing Information

The adjudication indicator decides whether exceeding the limit is worth appealing at all: MAI 1 is a line edit you can support with documentation, MAI 3 is a date-of-service edit that is also appealable, and MAI 2 is absolute, no documentation overrides it. CMS MUE 2026Q4.

The CMS record for J7517

Long descriptor
Mycophenolate mofetil, oral, 250 mg

The official wording. This is what the code means.

Short descriptor
Mycophenolate mofetil oral

CMS's 28-character form, which is what shows up on a remittance advice.

Added
January 1, 2000

When CMS introduced the code.

Terminated
September 30, 2026

When CMS retired it.

BETOS
O1E

Berenson-Eggers Type of Service: CMS's own analytic grouping.

Pricing indicator
51: Other

Drugs.

Codes adjacent to J7517

HCPCS has no hierarchy: related items simply sit next to each other in the numbering. If J7517 is not quite right, the correct code is very often within a few positions of it.

  • J7509Methylprednisolone oral, per 4 mg
  • J7510Prednisolone oral, per 5 mg
  • J7511Lymphocyte immune globulin, antithymocyte globulin, rabbit, parenteral, 25 mg
  • J7512Prednisone, immediate release or delayed release, oral, 1 mg
  • J7513Daclizumab, parenteral, 25 mgterminated
  • J7514Mycophenolate mofetil (myhibbin), oral suspension, 100 mgterminated
  • J7515Cyclosporine, oral, 25 mg
  • J7516Injection, cyclosporine, 250 mg
  • J7518Mycophenolic acid, oral, 180 mg
  • J7519Injection, mycophenolate mofetil, 10 mgterminated
  • J7520Sirolimus, oral, 1 mg
  • J7521Tacrolimus, granules, oral suspension, 0.1 mg
  • J7524Mycophenolate mofetil, oral, 5 mg
  • J7525Tacrolimus, parenteral, 5 mg
  • J7526Injection, mycophenolate mofetil, 5 mg
  • J7527Everolimus, oral, 0.25 mg
HCPCS Level II2026Q4-Oct· effective October 1, 2026